Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03752424Phase 1Unknown

Topical Silver Nanoparticles for Microbial Activity

Role: lead

NCT02882438Phase 1Unknown

Glucosamine Sulphate and Ginkgo Biloba as Antifungal Activity for Treating Tinea Pedis

Role: lead

NCT03774680Phase 1Unknown

Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer

Role: lead

NCT03772418Phase 1Unknown

Topical Preparation of Pomegranate and Ginkgo Biloba for Anti-aging Activities

Role: lead

All 4 trials loaded